Omega-3 (EPA/DHA) for Joint Pain
Long-chain polyunsaturated fatty acids from fish or algal oil that are incorporated into cell membranes and reduce pro-inflammatory eicosanoid production; linked to cardiovascular, joint, and neurological benefits.
Omega-3 (EPA/DHA) for Joint Pain
1 of 5 results reported a benefit, from 1 published study.
1 review of trials · the chart counts everything measured
- 1 reported a benefit
- 4 no clear benefit
Colour keyReported a benefitNo clear benefitUnclearPossible harmAmber is for highlights, such as where the most research is. It never means a result was good.
- Number of swollen jointsNo clear differencenegligible standardised effect1 review of trials2012 study ↗
- Number of tender jointsNo clear differenceslight standardised effect1 review of trials2012 study ↗
- Morning stiffnessNo clear differenceslight standardised effect1 review of trials2012 study ↗
- Physical functionNo clear differenceslight standardised effect1 review of trials2012 study ↗
Also measured in these studies (1)
These were measured alongside, but they are not what this condition is about.
- Anti-inflammatory painkiller useModerate effectmoderately better than the comparison group1 review of trials2012 study ↗
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every result is listed below.
See every resultThe connection
Joint discomfort, inflammation, arthritis and reduced mobility.
Also known as: Fish Oil, Krill Oil, EPA, DHA
Omega-3 (EPA/DHA) × Joint Pain: at a glance
Every published result for this pair, extracted and audited.
These charts count reported findings from published studies, grouped by reported benefit and study design. Study design is not a certainty grade.
Omega-3 (EPA/DHA) / Joint Pain: reported findings; one study may contribute several findings.
What the evidence shows
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| No benefit | 4 |
| Benefit | 1 |
Study designs behind these findings
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Meta-analysis | 5 |
- Studies
- 1
| Study | Outcome | Reported result | Uncertainty (as reported) | Study duration |
|---|---|---|---|---|
| Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. (PMID 22835600) | Morning stiffness | -0.224 standardized mean difference | 95% CI-0.955-0.212, p = 0.221 | 3 months |
| Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. (PMID 22835600) | NSAID consumption | -0.518 standardized mean difference | 95% CI -0.915 to -0.121, p = 0.011 | 3 months |
| Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. (PMID 22835600) | Physical function | 0.264 standardized mean difference | 95% CI-0.232-0.724, p = 0.314 | 3 months |
| Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. (PMID 22835600) | Swollen joint count | -0.170 standardized mean difference | 95% CI-0.454-0.114, p = 0.241 | 3 months |
| Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. (PMID 22835600) | Tender joint count | -0.214 standardized mean difference | 95% CI-0.489-0.062, p = 0.128 | 3 months |
Study results, as reported by the publications
Every measured outcome, one row per finding - numbers exactly as reported. Units are preserved where supplied; missing units are not inferred.
| Study and type | Reported sample and duration | Outcome measured | Reported result | What studies found |
|---|---|---|---|---|
| PMID 22835600 2012 Meta-analysis | Sample (as reported): Not reportedDuration: 3 months | Morning stiffness | -0.224 standardized mean difference (95% CI-0.955-0.212, p = 0.221) | No benefit |
| PMID 22835600 2012 Meta-analysis | Sample (as reported): Not reportedDuration: 3 months | NSAID consumption | -0.518 standardized mean difference (95% CI -0.915 to -0.121, p = 0.011) | Benefit |
| PMID 22835600 2012 Meta-analysis | Sample (as reported): Not reportedDuration: 3 months | Physical function | 0.264 standardized mean difference (95% CI-0.232-0.724, p = 0.314) | No benefit |
| PMID 22835600 2012 Meta-analysis | Sample (as reported): Not reportedDuration: 3 months | Swollen joint count | -0.170 standardized mean difference (95% CI-0.454-0.114, p = 0.241) | No benefit |
| PMID 22835600 2012 Meta-analysis | Sample (as reported): Not reportedDuration: 3 months | Tender joint count | -0.214 standardized mean difference (95% CI-0.489-0.062, p = 0.128) | No benefit |
Omega-3 (EPA/DHA) × Joint Pain: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Role of the EPA: DHA dosing ratio in omega-3 supplements on blood fatty acid profiles and inflammation: a systematic review and meta-analysisKhabir Z, et al. · Critical reviews in food science and nutrition · 2026PMID 41568426 ↗02Efficacy and Safety of Anti-nerve Growth Factor Monoclonal Antibodies in Managing Chronic Musculoskeletal Pain: A Systematic Review with Network Meta-analysisAbouelella A, et al. · Drugs · 2026PMID 41880116 ↗03Effect of collagen supplementation on knee osteoarthritis: an updated systematic review and meta-analysis of randomised controlled trialsSimental-Mendía M, et al. · Clinical and experimental rheumatology · 2025PMID 39212129 ↗04Efficacy of dietary supplements for treating knee osteoarthritis: a systematic review and network meta-analysisDu P, et al. · Frontiers in nutrition · 2025PMID 40123938 ↗05The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic ReviewBaden KER, et al. · Nutrients · 2025PMID 40647198 ↗06Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-AnalysisZhang Y, et al. · Nutrients · 2025PMID 40806131 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.